Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
Cancer|Neoplasm Metastasis
DRUG: TRC105 chimeric anti-CD105 antibody
Safety and Tolerability will be evaluated, Through last patient last visit|Dose Limiting Toxicities, 28 day evaluation period
Pharmacokinetics of TRC105 monoclonal antibody, through last patient last visit|Number of responses by tumor type, through last patient last visit
In addition to safety, this study will also evaluate pharmacokinetics, tumor response and anti-TRC105 antibody formation.